众生药业：控股子公司获得一类创新药昂拉地韦颗粒III期临床试验伦理批件

Core Viewpoint - The company announced that its subsidiary, Zhongsheng Ruichuang, has received ethical approval from Beijing Children's Hospital to conduct a Phase III clinical trial of Angladiwei granules in children aged 2 to 11 years with uncomplicated influenza A [1] Group 1 - The ethical approval allows the company to proceed with clinical trials specifically targeting a pediatric population [1] - The focus of the trial is on the treatment of uncomplicated influenza A in children, which indicates a strategic move to expand the company's product offerings in the pediatric market [1]